COMORBIDITY BETWEEN OBESITY AND MIGRAINE, POSSIBLE IMPACT OF GLP-1 RECEPTOR AGONISTS ON THE COURSE OF MIGRAINE – A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6163Keywords:
Migraine, Obesity, GLP-1 Receptor Agonists, Neuroinflammation, Metabolic DysfunctionAbstract
Background: Migraine and obesity share several metabolic triggers. It is a well-documented problem. Excess body weight actively fuels systemic inflammation and insulin resistance, which frequently pushes episodic headaches into a chronic daily struggle. Pharmaceutical companies originally designed GLP-1 receptor (GLP-1R) agonists for diabetes and weight control. However, neurologists are now looking at these drugs because they show strong anti-inflammatory and nerve-protecting effects.
Aim: We wanted to map exactly how obesity connects to migraine biology. We also evaluated whether prescribing GLP-1R agonists makes sense as a real-world headache treatment.
Material and methods: Our team searched databases like PubMed, Embase, Web of Science, and Google Scholar. We mostly pulled studies published between 2016 and 2026. We rejected isolated case reports entirely, focusing on randomized trials or solid observational data instead. Artificial intelligence helped us fix grammar and check text patterns — human experts handled all the actual analysis.
Results: The drugs appear to work in two main ways. On a cellular level, GLP-1R agonists shut down hyperactive microglial cells, lower CGRP levels in the trigeminal system, and physically block TRPV1 pain receptors. Systemically, they force the body to lose weight, drop the fluid pressure inside the skull, and help the brain absorb glucose better. It isn't a perfect fix, though. Many patients report temporary new headaches when they first start the medication. On top of that, recent models show these drugs can cause OnabotulinumtoxinA therapies to wear off much faster than usual.
Conclusions: Using GLP-1R agonists to treat chronic migraine makes biological sense. It is an especially logical option for patients dealing with severe obesity. However, doctors still have to watch out for early side effects and drug interactions. We need massive clinical trials before anyone can confirm their long-term safety.
References
Braca, S., Russo, C. V., Stornaiuolo, A., Cretella, G., Miele, A., Giannini, C., & De Simone, R. (2025). Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study. Headache: The Journal of Head and Face Pain, 65, 1831–1838. https://doi.org/10.1111/head.14991
Cervoni, C., Bond, D. S., & Seng, E. K. (2016). Behavioral weight loss treatments for individuals with migraine and obesity. Current Pain and Headache Reports, 20(13). https://doi.org/10.1007/s11916-016-0540-5
Denney, [First Initial]., & Marmura, M. J. (2026). [Impact of weight and lifestyle intervention on migraine]. Current Pain and Headache Reports, 30(61). https://doi.org/10.1007/s11916-026-01500-9
Fang, S., Cui, F., & Drucker, D. J. (2025). Glucagon-like peptide-1 medicines in neurological and psychiatric disorders. Cell Reports Medicine, 6, 102511. https://doi.org/10.1016/j.xcrm.2025.102511
Ferreira, E. T., Garcia, L. M. P., & Londero, R. G. (2025). Headache and GLP-1 receptor agonists: When medications are therapeutic and when they contribute to the symptom. Arquivos de Neuro-Psiquiatria, 83(10), s00451812303. https://doi.org/10.1055/s-0045-1812303
Halloum, W., Dughem, Y. A., Beier, D., & Pellesi, L. (2024). Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: A systematic review. The Journal of Headache and Pain, 25(112). https://doi.org/10.1186/s10194-024-01821-3
Jing, F., Zou, Q., Wang, Y., Cai, Z., & Tang, Y. (2021). Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation. The Journal of Headache and Pain, 22(86). https://doi.org/10.1186/s10194-021-01302-x
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022). Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacological Research, 186, 106550. https://doi.org/10.1016/j.phrs.2022.106550
Kristoffersen, E. S., Børte, S., Hagen, K., Zwart, J.-A., & Winsvold, B. S. (2020). Migraine, obesity and body fat distribution – A population-based study. The Journal of Headache and Pain, 21. https://doi.org/10.1186/s10194-020-01163-w
Modestino, E. J., et al. (2024). Hemiplegic migraines exacerbated using an injectable GLP-1 agonist for weight loss. Acta Scientific Neurology, 7(5), 12–18. https://doi.org/10.31080/asne.2024.07.0731
Pavlovic, J. M., Vieira, J. R., Lipton, R. B., & Bond, D. S. (2017). Association between obesity and migraine in women. Current Pain and Headache Reports, 21(41). https://doi.org/10.1007/s11916-017-0634-8
Peterlin, B. L., Rosso, A. L., Rapoport, A. M., & Scher, A. I. (2010). Obesity and migraine: The effect of age, gender and adipose tissue distribution. Headache, 50(4), 631–648. https://doi.org/10.1111/j.1526-4610.2009.01554.x
Pippi, R., Prete, D., Alabiso, M., & Sarchielli, P. (2025). Nutrition and physical activity in an interdisciplinary approach to migraine: A narrative review. Nutrients, 17, 3869. https://doi.org/10.3390/nu17243869
Rahman, E., Michon, A., Rao, P., Ahmed, M., Joseph, J. H., Wu, W. T. L., Carruthers, J. D. A., & Webb, W. R. (2026). Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin a: Evidence for reduced treatment durability across neurologic and aesthetic indications. Toxicon, 269, 108638. https://doi.org/10.1016/j.toxicon.2025.108638
Recober, A., & Goadsby, P. J. (2010). Calcitonin gene-related peptide (CGRP): A molecular link between obesity and migraine? Drug news & perspectives, 23(2), 112–117. https://doi.org/10.1358/dnp.2010.23.2.1475909
Seng, E. K., Martin, P. R., & Houle, T. T. (2022). Lifestyle factors and migraine. Lancet Neurology, 21, 911–921. https://doi.org/10.1016/S1474-4422(22)00211-3
Shibata, Y. (2022). Migraine pathophysiology revisited: Proposal of a new molecular theory of migraine pathophysiology and headache diagnostic criteria. International Journal of Molecular Sciences, 23, 13002. https://doi.org/10.3390/ijms232113002
Sulter, G. A. (2026). Glucagon-like peptide-1 receptor agonists in chronic migraine: A convergent disease-modification hypothesis. Preprints.org, 202605.0916.v1. https://doi.org/10.20944/preprints202605.0916.v1
Sun, X., Song, J., et al. (2025). The association between lipid-related obesity indicators and severe headache or migraine: A cross-sectional study. Lipids in Health and Disease, 24(10). https://doi.org/10.1186/s12944-025-02432-w
Verrotti, A., Di Fonzo, A., Penta, L., Agostinelli, S., & Parisi, P. (2014). Obesity and headache/migraine: The importance of weight reduction through lifestyle modifications. BioMed Research International, 2014, 420858. https://doi.org/10.1155/2014/420858
Zobdeh, F., ben Kraiem, A., Attwood, M. M., Chubarev, V. N., Tarasov, V. V., Schiöth, H. B., & Mwinyi, J. (2021). Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. British Journal of Pharmacology, 178(23), 4588–4607. https://doi.org/10.1111/bph.15657
Aykan, D. A., Kesim, M., Ayan, B., Kurt, A. (2019). Anti-inflammatory and antinociceptive activities of glucagon-like peptides: Evaluation of their actions on serotonergic, nitrergic, and opioidergic systems. Psychopharmacology (Berl). 2019 Jun;236(6):1717-1728. https://doi.org/10.1007/s00213-018-5154-7
Ma, L., Ju, P., Wang, W., Wei, J., Wang, W., Zhao, M., Ahmad, K. A., Wang, Y., Chen, J. (2021). Microglial activation of GLP-1R signaling in neuropathic pain promotes gene expression adaption involved in inflammatory responses. Neural Plast. 2021 Aug 31;2021:9923537. https://doi.org/10.1155/2021/9923537
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Inga Kokuszko, Blanka Buszta, Weronika Kopniak, Katarzyna Agnieszka Góra, Sebastian Konopko, Wiktoria Wasilewska, Zuzanna Maria Paszt

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

